Christian D. Diehl

Dr. Christian D. Diehl


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CDChristian D. Diehl
Christian D. Diehl
SPSteffi Pigorsch
Steffi Pigorsch
JGJens Gempt
Jens Gempt
Sandro M KriegSandro M Krieg
Sandro M Krieg
SRSilvia Reitz
Silvia Reitz
SCStephanie Combs
Stephanie Combs
Background: Resection followed by local radiation therapy (RT) is the standard of care for symptomatic brain metastases. However, the optimal technique, fractionation scheme and dose are still being debated. Lately, low-energy X-ray intraoperative RT (lex-IORT) has been of increasing interest. Method: Eighteen consecutive patients undergoing BM resection followed by immediate lex-IORT with 16–30 Gy applied to the spherical applicator were retrospectively analyzed. Demographic, RT-specific, radiographic and clinical data were reviewed to evaluate the effectiveness and safety of IORT for BM. Descriptive statistics and Kaplan–Meyer analysis were applied. Results: The mean follow-up time was 10.8 months (range, 0–39 months). The estimated local control (LC), distant brain control (DBC) and overall survival (OS) at 12 months post IORT were 92.9% (95%-CI 79.3–100%), 71.4% (95%-CI 50.2–92.6%) and 58.0% (95%-CI 34.1–81.9%), respectively. Two patients developed radiation necrosis (11.1%) and wound infection (CTCAE grade III); both had additional adjuvant treatment after IORT. For five patients (27.8%), the time to the start or continuation of systemic treatment was ≤15 days and hence shorter than wound healing and adjuvant RT would have required. Conclusion: In accordance with previous series, this study demonstrates the effectiveness and safety of IORT in the management of brain metastases despite the small cohort and the retrospective characteristic of this analysis.

1 September 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CDChristian D. Diehl
Christian D. Diehl
MSMaximilian J. Schwendner
Maximilian J. Schwendner
Nico SollmannNico Sollmann
Nico Sollmann
MOMarkus Oechsner
Markus Oechsner
BMBernhard Meyer
Bernhard Meyer
Sandro M KriegSandro M Krieg
Sandro M Krieg

31 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CDChristian D. Diehl
Christian D. Diehl
EREnrike Rosenkranz
Enrike Rosenkranz
MSMaximilian Schwendner
Maximilian Schwendner
MMMartin Mißlbeck
Martin Mißlbeck
Nico SollmannNico Sollmann
Nico Sollmann
Sandro M KriegSandro M Krieg
Sandro M Krieg
Background: Resection of brain metastases (BM) close to motor structures is challenging for treatment. Navigated transcranial magnetic stimulation (nTMS) motor mapping, combined with diffusion tensor imaging (DTI)-based fiber tracking (DTI-FTmot.TMS), is a valuable tool in neurosurgery to preserve motor function. This study aimed to assess the practicability of DTI-FTmot.TMS for local adjuvant radiotherapy (RT) planning of BM. Methods: Presurgically generated DTI-FTmot.TMS-based corticospinal tract (CST) reconstructions (FTmot.TMS) of 24 patients with 25 BM resected during later surgery were incorporated into the RT planning system. Completed fractionated stereotactic intensity-modulated RT (IMRT) plans were retrospectively analyzed and adapted to preserve FTmot.TMS. Results: In regular plans, mean dose (Dmean) of complete FTmot.TMS was 5.2 ± 2.4 Gy. Regarding planning risk volume (PRV-FTTMS) portions outside of the planning target volume (PTV) within the 17.5 Gy (50%) isodose line, the DTI-FTmot.TMS Dmean was significantly reduced by 33.0% (range, 5.9–57.6%) from 23.4 ± 3.3 Gy to 15.9 ± 4.7 Gy (p < 0.001). There was no significant decline in the effective treatment dose, with PTV Dmean 35.6 ± 0.9 Gy vs. 36.0 ± 1.2 Gy (p = 0.063) after adaption. Conclusions: The DTI-FTmot.TMS-based CST reconstructions could be implemented in adjuvant IMRT planning of BM. A significant dose reduction regarding motor structures within critical dose levels seems possible.

19 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CDChristian D. Diehl
Christian D. Diehl
FGFrank Anton Giordano
Frank Anton Giordano
AGAnca-Ligia Grosu
Anca-Ligia Grosu
SISebastian Ille
Sebastian Ille
KKKlaus-Henning Kahl
Klaus-Henning Kahl
SCStephanie Combs
Stephanie Combs
Postsurgical radiotherapy (RT) has been early proven to prevent local tumor recurrence, initially performed with whole brain RT (WBRT). Subsequent to disadvantageous cognitive sequalae for the patient and the broad distribution of modern linear accelerators, focal irradiation of the tumor has omitted WBRT in most cases. In many studies, the effectiveness of local RT of the resection cavity, either as single-fraction stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic RT (hFSRT), has been demonstrated to be effective and safe. However, whereas prospective high-level incidence is still lacking on which dose and fractionation scheme is the best choice for the patient, further ablative techniques have come into play. Neoadjuvant SRS (N-SRS) prior to resection combines straightforward target delineation with an accelerated post-surgical phase, allowing an earlier start of systemic treatment or rehabilitation as indicated. In addition, low-energy intraoperative RT (IORT) on the surgical bed has been introduced as another alternative to external beam RT, offering sterilization of the cavity surface with steep dose gradients towards the healthy brain. This consensus paper summarizes current local treatment strategies for resectable brain metastases regarding available data and patient-centered decision-making.

26 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RMRazan Muhtadi
Razan Muhtadi
Denise BernhardtDenise Bernhardt
Denise Bernhardt
Gabriele MulthoffGabriele Multhoff
Gabriele Multhoff
LHLisa Hönikl
Lisa Hönikl
SCStephanie Combs
Stephanie Combs
POPatrick Ostheim
Patrick Ostheim
GBM WHO CNS Grade 4 represents a major challenge for oncology due to its aggressive behavior. Conventional imaging has restrictions in detecting tumor recurrence. This prospective study aims to identify gene-based biomarkers in whole blood instead of isolating exosomes for the early detection of tumor recurrence. Blood samples (n = 33) were collected from seven GBM patients at time points before and after surgery as well as upon tumor recurrence. Four tumor tissue samples were assessed in parallel. Next-generation sequencing (NGS), including mRNA-seq and small RNA-seq, was used to analyze gene expression profiles in blood samples and tumor tissues. A novel filtering pipeline was invented to narrow down potential candidate genes. In total, between 6–93 mRNA and 1–19 small RNA candidates could be identified among the seven patients. The overlap of genes between the patients was minimal, indicating significant inter-individual variance among GBM patients. In summary, this prospective study supports the applicability of gene expression measurements in whole blood for the detection of tumor recurrence. It might provide an alternative to the challenging workflow of liquid biopsy after laborious exosome isolation from whole blood.

18 April 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
CDChristian D. Diehl
Christian D. Diehl
EREnrike Rosenkranz
Enrike Rosenkranz
MMMartin Mißlbeck
Martin Mißlbeck
MSMaximilian Schwendner
Maximilian Schwendner
Nico SollmannNico Sollmann
Nico Sollmann
Sandro M KriegSandro M Krieg
Sandro M Krieg